Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Tohen, M. Articles by Biederman, J. Search for Related Content PubMed Citation Articles by Tohen, M. Articles by Biederman, J. Child/Adolescent Psychiatry Bipolar Disorder Related Article

Olanzapine Versus Placebo in the Treatment of Adolescents With Bipolar Mania

OBJECTIVE: The purpose of this study was to evaluate the efficacy and safety of olanzapine for the treatment of acute manic or mixed episodes associated with bipolar disorder in adolescents. METHOD: A 3-week multicenter, parallel, double-blind, randomized placebo-controlled trial was conducted at 24 sites in the United States and two sites in Puerto Rico. The participants were outpatient and inpatient male and female adolescents 13–17 years of age with an acute manic or mixed episode. Subjects received either olanzapine (2.5–20 mg/day [N=107]) or placebo (N=54). The mean change from baseline to endpoint in the Young Mania Rating Scale total score was the primary outcome measure. RESULTS: The mean baseline-to-endpoint change in the Young Mania Rating Scale total score was significantly greater for patients receiving olanzapine relative to patients receiving placebo, and a greater proportion of olanzapine-treated patients met response and remission criteria (44.8% versus 18.5% and 35.2% versus 11.1%, respectively). The mean baseline-to-endpoint weight change was significantly greater for patients receiving olanzapine relative to patients receiving placebo (3.7 kg versus 0.3 kg), and the incidence of treatment-emergent weight gain 7% of baseline was higher for olanzapine-treated patients (41.9% versus 1.9%). The mean baseline-to-endpoint changes in prolactin, fasting glucose, fasting total cholesterol, uric acid, and the hepatic enzymes aspartate transaminase and alanine transaminase were significantly greater in patients treated with olanzapine relative to patients receiving placebo. CONCLUSIONS: Olanzapine was effective in the treatment of bipolar mania in adolescent patients. Patients treated with olanzapine, however, had significantly greater weight gain and increases in the levels of hepatic enzymes, prolactin, fasting glucose, fasting total cholesterol, and uric acid.

Related Article:

In This Issue
Am J Psychiatry 2007 164: A34. [Full Text] [PDF]

This article has been cited by other articles:

				B. Geller, R. Tillman, K. Bolhofner, and B. Zimerman Child Bipolar I Disorder: Prospective Continuity With Adult Bipolar I Disorder; Characteristics of Second and Third Episodes; Predictors of 8-Year Outcome Arch Gen Psychiatry, October 1, 2008; 65(10): 1125 - 1133. [Abstract] [Full Text] [PDF]

				S. E. Meyer and G. A. Carlson Early-Onset Bipolar Disorder Focus, June 1, 2008; 6(3): 271 - 283. [Abstract] [Full Text] [PDF]

				C. U. Correll Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes Focus, June 1, 2008; 6(3): 368 - 378. [Abstract] [Full Text] [PDF]

				Mania in Teens: How to Treat? Journal Watch Psychiatry, November 19, 2007; 2007(1119): 1 - 1. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us